Iterum Therapeutics (ITRM) Q2 2025 earnings summary

Executive summary

• ORLYNVAH, a novel oral penem antibiotic for uUTIs, is set for U.S. commercial launch in August 2025, ahead of schedule, marking the first branded antibiotic for uUTIs in over 25 years and targeting a significant unmet need in at-risk women.

• Strategic partnerships established with EVERSANA for commercialization and ACS Dobfar for manufacturing and supply, including a five-year commercialization agreement.

• The initial commercial focus is on 20 high-value territories across seven states, with a sales team targeting 2,300 high-prescribing physicians.

• A new Chief Commercial Officer with extensive experience has been hired to lead the launch.

• Ongoing business development discussions for potential sale or licensing of sulopenem rights, though no transaction has been completed.

Financial highlights

• Net loss for Q2 2025 was $6.5 million, compared to $5.0 million in Q2 2024; non-GAAP net loss was $5.1 million, up from $3.8 million.

• Operating expenses for Q2 2025 were $5.5 million, up from $4 million in Q2 2024, driven by increased G&A for pre-commercialization.

• R&D expenses decreased to $1 million from $2.1 million year-over-year due to lower clinical trial costs.

• General and administrative expenses rose to $4.2 million from $1.9 million, mainly due to pre-commercialization activities.

• Cash and cash equivalents stood at $13 million at the end of June 2025, with an additional $2.2 million raised post-quarter.

Outlook and guidance

• Cash and equivalents, plus $2.2 million raised post-quarter, are expected to fund operations into 2026, including the commercial launch.

• Plans to expand commercial resources and territories if the initial launch phase is successful.

• Annual general meeting will seek authorization to double share capital, providing financial flexibility for future funding.

• Additional capital is required to support ongoing activities, with substantial doubt about going concern status if not secured.

• Ongoing evaluation of strategic, financial, and corporate alternatives to maximize stakeholder value.